scholarly journals Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination

2022 ◽  
Vol 8 (1) ◽  
Author(s):  
Xiaoqi Yu ◽  
Dong Wei ◽  
Wenxin Xu ◽  
Yulong Li ◽  
Xinxin Li ◽  
...  

Aflatoxin M1 is one of mycotoxin derivatives, which is secreted in milk of dairy cattle fed on feed contaminated with Aflatoxin-B1 (AFB1). The current study was designed to prepare a vaccine against AFB1and to evaluate its efficacy in reducing or preventing secretion of AFM1 in milk. Aflatoxin-B1 was prepared, purified and transformed into oxime, then it was fixed on bovine serum albumins. The AFB1-BSA conjugate was adjuvanted with Gold Nano particles then Montanide ISA 206. The prepared vaccine was used for immunization of rabbits by S/c routes as 100 µg/dose and dairy cattle by I/M routes as 500 µg/dose. The vaccinated animals were boosted at 3 weeks post primary immunization. Serum samples were collected and examined for the anti-AFB1 using AGPT. A mean titer of 15.2 AGPU/ml was detected at 2 weeks post primary vaccination then significantly increased till reached to 76.8 AGPU/ml at 6 weeks post Booster vaccination. All vaccinated rabbits were challenged with dose of 0.3 mg AFB1 toxin/Kg. The vaccinated rabbit showed 100% protection and no AFB1 toxin residue was detected in their livers. Milk samples were collected from non-vaccinated and AFB1-immunized dairy cattle then examined with ELISA for quantitation of AFM1 residues before and after vaccination. The results showed that the prepared AFB1 vaccine was safe, potent and able to reduce AFM1 release in milk of vaccinated heifers by 70%. So the vaccination of lactating animals with the AFB1vaccine might represent a valid tool for the prevention of AFM1 contamination of milk and dairy products.


EBioMedicine ◽  
2021 ◽  
Vol 68 ◽  
pp. 103420
Author(s):  
Pauline Versteegen ◽  
Marta Valente Pinto ◽  
Alex M. Barkoff ◽  
Pieter G.M. van Gageldonk ◽  
Jan van de Kassteele ◽  
...  

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 501
Author(s):  
Chung-Jong Kim ◽  
Ji-Yun Bae ◽  
Kang-Il Jun ◽  
Hae-Sun Chung ◽  
Aeyeon Kim ◽  
...  

We aimed to identify the presence of the measles IgG antibody (mIgG-Ab) in healthcare personnel and finding out who needs the measles vaccination. The history of measles vaccination was obtained from the national vaccine registry. A baseline mIgG-Ab test was performed, and the measles vaccine was administered to participants who tested negative or equivocal for mIgG-Abs. During the study, 2885 (87.3%) of the 3303 employees were tested for measles serostatus. The baseline seropositivity rate for mIgG-Abs was 91.9%. Among the 234 seronegative cases, 82.9% were born after 1985. The seroprevalence rate was lower in those who received the measles–mumps–rubella (MMR) vaccine >10 years before the testing time, especially if they were born after 1985 and if there was only one previous record of vaccination. Among the 234 seronegative cases, MMR vaccination was administered in 174 cases, of which serostatus was evaluated in 146 cases. After the first dose, positive seroconversion was achieved in 126 participants (86.3%). After a second dose, 15 achieved (75.0%) positive seroconversion. In healthcare personnel born after the period when measles incidence significantly decreased, it may be necessary to reassess their immune status for measles if more than 10 years have elapsed since the last vaccination.


2017 ◽  
Vol 13 (5) ◽  
pp. e1006313 ◽  
Author(s):  
Oliver F. Brandenberg ◽  
Carsten Magnus ◽  
Peter Rusert ◽  
Huldrych F. Günthard ◽  
Roland R. Regoes ◽  
...  

2008 ◽  
Vol 27 (3) ◽  
pp. 218-223 ◽  
Author(s):  
Sabine C. de Greeff ◽  
Frits R. Mooi ◽  
Joop F. P. Schellekens ◽  
Hester E. de Melker

Sign in / Sign up

Export Citation Format

Share Document